$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
028-123456789
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
medicaldrugs
medicaldrugs
Is there a risk of platelet decline while taking Eltrombopag (Revlan)?
2026-02-01 22:25:32
Check Details
Guidelines for the best taking time and medication intervals of Roprostim (Huierning)
2026-02-01 22:25:32
Check Details
Analysis of which disease types and patient populations Midostaurin is suitable for
2026-02-01 22:25:32
Check Details
Analysis of the main functions and clinical applications of cabergoline
2026-02-01 22:25:32
Check Details
Standard dosage and safe medication recommendations for Momelotinib
2026-02-01 22:25:32
Check Details
Common side effects and symptoms of Biken Pronol Tablets (Bituvi)
2026-02-01 22:25:32
Check Details
Detailed instructions and medication guide for decavatinib
2026-02-01 22:25:32
Check Details
What is the actual efficacy of Apremilast (Otelac)? Patient feedback and clinical observations
2026-02-01 22:25:32
Check Details
What kind of drugs does Valganciclovir belong to and its clinical pharmacological effects?
2026-02-01 22:25:32
Check Details
Analysis of the efficacy of Shafinamide Tablets (Siddaco) and its clinical efficacy in Parkinson’s patients
2026-02-01 22:25:32
Check Details
Tarlatamab-Imdelltra official instructions and instructions for use
2026-02-01 22:25:32
Check Details
Analysis of whether telisotuzumab-EMRELIS has been included in medical insurance and reimbursement policies and conditions
2026-02-01 22:25:32
Check Details
1
2
...
2250
2251
2252
2253
2254
2255
2256
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
User Agreement
2
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
3
What is the most important information I should know about WELIREG?
4
How to take and store WELIREG
5
How to take TRUSELTIQ correctly
6
How to deal with LONSURF side effects (1)
7
How to deal with LONSURF side effects (2)
8
Cabozantinib (Cabometyx)-new indication approved
9
What should I pay attention to when using atezolizumab/Tecentriq?
10
Darzalex Faspro, Kyprolis and dexamethasone "three swords combined" to treat multiple myeloma
11
Rituximab combined with chemotherapy approved in the United States for pediatric patients with specific malignant tumors
12
Lenvatinib and pembrolizumab trial results in unresectable hepatocellular carcinoma